Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

Fig. 2

Intracellular cytokine staining (ICS) of CVac-treated patients. Values are corrected for the background (endogenous unstimulated response) subtracted from the mucin 1 (MUC1) challenge shown as a percentage. Values of zero or less are shown as zero. The samples shown represent those patients that had both a baseline sample and a visit 13 sample (completion of 10 doses of CVac treatment) available for analysis

Back to article page